应用于骨再生医学的干细胞及药物治疗骨质疏松:现状与未来  

Drug therapies for osteoporosis and application of stem cells in bone regeneration medicine:the current and future

作　　者：林源[1] 陶树清[1] 

机构地区：[1]哈尔滨医科大学附属第二医院骨二科,黑龙江省哈尔滨市150001

出　　处：《中国组织工程研究》2015年第19期3107-3111,共5页Chinese Journal of Tissue Engineering Research

摘　　要：背景:除药物治疗外,利用再生医学方法治疗骨质疏松是目前全球研究的热点,寻找对患者创伤相对较小、更合适的种子细胞也是关注的重点。目的:了解药物治疗骨质疏松及干细胞应用于骨再生医学的研究现状及最新进展。方法:由第一作者应用计算机检索Pub Med数据库2000年1月至2014年12月相关文献。在标题、摘要、关键词中以"osteoporosis,drug therapy,bone regenerative medicine,stem cell therapy"为检索词进行检索并查阅其相关参考文献,最终选择39篇文献进行综述。结果与结论:来自日本的Yoshikazu Mikami等人通过人工合成色氨酸衍生物发现了两种新型骨形成促进剂——SST-VEDI和SSH-BMI,为相关药物研究提供了一个新的方向。去分化脂肪细胞和牙髓干细胞因其具有成骨方向分化能力且创伤小、伦理争议小等具有广阔的应用前景。BACKGROUND： Besides drug therapy, regenerative therapy is now a matter of global interest in treating osteoporosis. Therefore, it is also important to find better candidate cells. OBJECTIVE： To cognize the status of drug therapies for osteoporosis and stem celts as regenerative therapy. METHODS： A computer-based search of PubMed was performed by the first author to retrieve articles relevant to stem cell therapy for osteoporosis published from January 2000 to December 2014. The keywords were ＂osteoporosis, drug therapy, bone regenerative medicine, stem cell therapy＂, which appeared in the title, abstract or keywords, and the relevant references were also looked up. Articles published recently or in authoritative journals were preferred, and finally 39 articles were included in result analysis. RESULTS AND CONCLUSION： Yoshikazu Mikami and co-workers from Japan found two novel bone formation accelerators, SST-VEDI and SSH-BMI, which provides a new direction for related studies on drug therapy. Due to the osteogenesis ability, lack of ethical controversy and less damage, de-differentiated fat cells and pulp stem cells may be promising candidate cells for bone regeneration medicine.

关 键 词：骨质疏松 骨再生 干细胞 药物疗法 药物治疗 骨再生医学 SST-VEDI SSH-BMI 去分化脂肪细胞 牙髓干细胞 

分 类 号：R318[医药卫生—生物医学工程]